Media coverage about STERIS (NYSE:STE) has trended somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. STERIS earned a coverage optimism score of 0.13 on Accern’s scale. Accern also gave media coverage about the medical equipment provider an impact score of 46.4736537826457 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the headlines that may have effected Accern’s scoring:
A number of equities research analysts have recently issued reports on the stock. Zacks Investment Research upgraded shares of STERIS from a “hold” rating to a “buy” rating and set a $104.00 target price on the stock in a research note on Thursday, April 5th. KeyCorp reiterated a “buy” rating and set a $103.00 price objective on shares of STERIS in a research note on Thursday, February 8th. Northcoast Research set a $102.00 price objective on shares of STERIS and gave the stock a “buy” rating in a research note on Thursday, February 8th. Finally, Raymond James Financial reiterated a “market perform” rating and set a $100.00 price objective on shares of STERIS in a research note on Wednesday, January 3rd. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $85.40.
STE traded up $0.02 on Friday, hitting $94.41. 209,243 shares of the company’s stock were exchanged, compared to its average volume of 344,704. The firm has a market cap of $8,008.81, a price-to-earnings ratio of 25.11 and a beta of 1.12. STERIS has a twelve month low of $69.27 and a twelve month high of $96.43. The company has a quick ratio of 2.22, a current ratio of 2.82 and a debt-to-equity ratio of 0.46.
STERIS (NYSE:STE) last released its quarterly earnings data on Wednesday, February 7th. The medical equipment provider reported $1.12 earnings per share for the quarter, topping the consensus estimate of $1.07 by $0.05. The firm had revenue of $661.90 million for the quarter, compared to analyst estimates of $663.17 million. STERIS had a net margin of 9.42% and a return on equity of 11.57%. STERIS’s quarterly revenue was up 2.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.98 earnings per share. research analysts anticipate that STERIS will post 4.13 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, March 28th. Investors of record on Wednesday, February 28th were paid a dividend of $0.31 per share. This is a positive change from STERIS’s previous quarterly dividend of $0.21. The ex-dividend date was Tuesday, February 27th. This represents a $1.24 annualized dividend and a yield of 1.31%. STERIS’s dividend payout ratio is 32.98%.
In other STERIS news, Director Richard Martin Steeves sold 58,953 shares of the firm’s stock in a transaction that occurred on Monday, March 5th. The shares were sold at an average price of $91.00, for a total value of $5,364,723.00. Following the sale, the director now owns 9,362 shares in the company, valued at $851,942. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Walter M. Rosebrough, Jr. sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, March 12th. The shares were sold at an average price of $95.50, for a total transaction of $955,000.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 78,415 shares of company stock worth $7,178,536. 2.55% of the stock is owned by company insiders.
COPYRIGHT VIOLATION WARNING: This article was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/04/16/steris-ste-receiving-somewhat-positive-media-coverage-study-shows.html.
STERIS plc develops, manufactures, and markets infection prevention, contamination control, microbial reduction, and surgical and gastrointestinal support products and services for healthcare, pharmaceutical, scientific, research, industrial, and governmental customers worldwide. The company's Healthcare Products segment offers steam, vaporized hydrogen peroxide, and ethylene oxide sterilizers, as well as liquid chemical sterilant processing systems; automated washer/disinfector systems; general and specialty surgical tables, surgical and examination lights, equipment management systems, operating room storage cabinets, warming cabinets, scrub sinks, and other accessories; and gastrointestinal devices and accessories.
Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.